VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting
Visioneering Technologies, Inc. (ASX:VTI), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, presented interim data from the PROTECT Clinical Trial at the American Academy of Optometry's annual meeting. Interim 1-year data from the PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) clinical trial, conducted across four countries, demonstrated the safety and effectiveness of NaturalVue Multifocal (“NVMF”) contact lenses in controlling myopia progression in pediatric patients.
The preliminary 1-year findings affirmed NVMF’s effectiveness in slowing myopia progression. Over 12 months, the treatment effect yielded a 69% (0.41Diopter) reduction in refractive error compared to the control group. For axial length, the treatment effect measured 0.17 mm, a notable 59% reduction. This data aligns with prior real-world analyses, further validating NVMF’s efficacy.
Note: Preliminary data; further review and analysis to be completed; additional insights to be shared in January 2024.
Dr. Ashley Tuan, VTI's Chief Medical Officer, expressed:
"The preliminary 1-year data confirms our belief in the safety and effectiveness of NaturalVue Multifocal for pediatric patients. NVMF not only ensures clear vision but also effectively manages myopia. The interim 1-year treatment effects are consistent with those of the only treatment approved by the U.S. Food and Drug Administration for myopia progression control. We eagerly anticipate sharing more insights from the study."
VTI's CEO, Dr. Juan Carlos Aragón, added:
"VTI's innovative and easily adaptable lens design plays a pivotal role in tackling pediatric myopia, one of the most pressing concerns in optometry today. We're thrilled to unveil the 1-year interim results of our PROTECT RCT, demonstrating the effectiveness of NaturalVue Multifocal in managing myopia in children."
To download the PROTECT Fact Sheet, click here. Visioneering Technologies Inc. focuses on groundbreaking vision care solutions, with its flagship product being the NaturalVue Multifocal 1-Day Contact Lens. For more information, visit www.vtivision.com or call +1 844-884-5367, ext. 104.
*Modified PP (Per Protocol) analysis including children between baseline ages 8 and <13 with refractive error between -0.75 and -4.00 D versus age-matched controls wearing spherical lenses. SD = standard deviation
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Layna L. Mendlinger
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting28.2.2024 07:00:00 CET | Press release
Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio. Galderma’s extensive presence – including two late-breaking presentations on its first-in-class, investigational monoclonal antibody nemolizumab, five oral poster presentations, 16 e-posters, a symposium, and several ‘Meet the Expert’ and interactive booth sessions – highlights its commitment to listening to consumers, patients and healthcare professionals in order to deliver cutting-edge science and innovation that addresses their varied needs. “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action. We particularly look forward to presenting the latest updates from
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease27.2.2024 22:08:00 CET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024. The BLA is supported by positive data from the AGAVE-201 trial (NCT04710576), recently highlighted in a Plenary Scientific Session at the American Society of Hematology Annual Meeting 2023, which showed that treatment with axatilimab resulted in clinically meaningful results and was generally well-tolerated, with a safety profile that was manageable and consistent with the mechanism of action of CSF-1R inhibition. Axatilimab is being developed by Incyte and Syndax Pharmaceuticals (Nasdaq:SNDX) as part of an exclusive worldwide co-development and co-commercialization license agree
Stonebranch Announces Record-Breaking Growth in 2023, Sets Sights on Future Innovations27.2.2024 19:24:00 CET | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry. New Customer and Partner Relationships Fuel Growth In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach. Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations
INRED to Provide Wi-Fi Services to Remote Areas in Colombia via SES Satellites27.2.2024 18:06:00 CET | Press release
Following a series of successful collaborations to close the digital divide, Colombian local connectivity service provider INRED and SES announced today they will deliver high-throughput satellite services for Colombia’s Ministry of Information and Communication Technologies (MinTic) to support digital inclusion projects across the country. INRED will utilise SES’s Managed Enterprise service delivered via its Geostationary Earth Orbit (GEO) satellites to connect 300 new sites, including those in remote areas that cannot be reached by traditional, fiber-based terrestrial networks. As part of the project called "Zonas Comunitarias para la Paz", INRED will provide free Wi-Fi services to historically unconnected areas across Colombia via SES’s high throughput SES-17 and SES-14 satellites. The enhanced connectivity services will allow INRED to quickly deliver broadband services to 300 sparsely-populated areas, with the ability to easily scale up capacity in the future if needed. INRED and S
Türk Telekom Achieves the World’s First Mass Deployment of Software-defined Fiber Broadband With Zyxel and Netsia27.2.2024 16:54:00 CET | Press release
Türk Telekom, pioneer of digital transformation Türkiye, has completed the world’s first mass deployment of Software-Defined Fiber Broadband. By using Netsia’s BB Suite and Zyxel’s Whitebox OLT, Türk Telekom has taken an important step towards fulfilling its virtualized and disaggregated broadband network strategy and thus, providing world-class, modern, high quality and high-speed broadband services. “Beyond our role as a telecommunications operator, we are leading Türkiye's ambition to become a significant player in technology exports through our pioneering initiatives and partnerships. While supporting our local ecosystem through collaborations within our country, we are also elevating the prestige and value of our nation through our global endeavors," says Ümit Önal, CEO at Türk Telekom. “The cutting-edge fiber infrastructure technology product Zyxel, developed by Argela, our company renowned for innovative solutions, along with its US subsidiary Netsia, has evolved into an innovat